Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another instalment of The Health Kick Podcast. 

In this episode Tim chats to Nina Webster, CEO & managing director at Dimerix (ASX:DXB).

Dimerix is a clinical-stage biopharmaceutical company developing innovative new therapies in areas with unmet medical needs for global markets.

Dimerix has welcomed recent news that the FDA has approved the drug Sparsentan for Immunoglobulin A nephropathy (IgAN) another type of rare (orphan) kidney disease. The company says this approval is further validation of the opportunity for its drug candidate DMX-200 for Focal Segmental Glomerulosclerosis (FSGS) kidney disease

Dr Webster says they expect first data from their DMX200 trial by the end of the year.

To hear Tim and Nina discuss all this and more, click below!